MCL Literature Feed

This case report describes the specific sonographic features of mantle cell lymphoma presenting as an inguinal mass, which can aid radiologists in the differential diagnosis of regional lymphadenopathy.

The frontline, chemotherapy-free triplet of acalabrutinib, venetoclax, and rituximab achieved 100% ORR and high MRD negativity, establishing a potent, time-limited option despite significant COVID-19 toxicity.

This review synthesizes current data and practical considerations for CAR-T and bispecific antibodies, guiding clinical decision-making and sequencing for these T-cell engaging therapies in relapsed/refractory MCL.

In older, frontline MCL patients, adding bortezomib to BR induction or lenalidomide to rituximab maintenance did not improve PFS, confirming BR-R as a highly effective standard.

This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.

This CML review details targeting the ubiquitin-proteasome system to overcome TKI resistance, offering a potential mechanistic strategy for addressing BTKi resistance in MCL.

A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.

The non-covalent BTK inhibitor pirtobrutinib is now approved in Japan for mantle cell lymphoma, providing a crucial new therapeutic option for patients, including those resistant to covalent BTKis.

This preclinical study identifies the CERS6-AS1/FGFR1 axis as a synthetic vulnerability, offering a novel therapeutic strategy to disrupt stromal cell-mediated proliferation and overcome resistance in MCL.

Hyperleukocytosis from undiagnosed leukemic MCL interfered with an HbA1c test, revealing a novel diagnostic pathway where a common diabetes lab test can signal an underlying hematologic malignancy.

Preclinically, dual inhibition of Hedgehog/GLI1 and Wnt/β-catenin pathways synergistically suppresses MCL cells and enhances sensitivity to chemotherapy and ibrutinib, suggesting a new approach to overcome resistance.

This first-reported case of sphenoid sinus MCL causing acute bilateral blindness demonstrates that prompt chemo-surgical intervention can partially reverse vision loss, highlighting a rare but critical CNS presentation.

This review synthesizes current and emerging therapies for relapsed/refractory MCL, including BTKi, BCL2i, CAR-T, and bispecifics, emphasizing the evolving challenge of post-BTKi treatment sequencing.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.

Spatial multiomics reveals CD163+ macrophages activate the MAPK prosurvival pathway in MCL cells, identifying MAPK inhibitors as a potential therapy for patients with high macrophage infiltration.

A rare case of mantle cell lymphoma discovered incidentally within a benign Warthin tumor highlights a diagnostic pitfall, underscoring the need to pathologically evaluate lymphoid stroma to avoid missed diagnoses.

Seven-year follow-up of venetoclax-ibrutinib in relapsed/refractory MCL shows durable responses (30% PFS) and demonstrates feasibility of MRD-guided treatment-free remission, supporting a long-term chemotherapy-free strategy.

This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.

A survey of US and European hematologists reveals significant knowledge gaps in MCL guidelines, molecular testing, and toxicity management, highlighting a need for improved continuing medical education.

Preclinical models show the PI3K inhibitor idelalisib synergizes with the CDK4/6 inhibitor palbociclib, providing a rationale for a novel combination therapy in relapsed/refractory MCL.

This case report documents a rare presentation of mantle cell lymphoma as complete heart block from cardiac metastasis, highlighting a critical differential diagnosis for unexplained conduction abnormalities.

This case report describes the rare simultaneous occurrence of recurrent hepatocellular carcinoma and mantle cell lymphoma, highlighting the diagnostic and therapeutic challenges of managing co-existing malignancies.

Preclinical data shows the novel CTPS1 inhibitor STP-B has single-agent activity in high-risk MCL (blastoid, TP53-mutated) and synergizes with venetoclax by downregulating MCL1, offering a new combination strategy.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

This case report details an extremely rare presentation of relapsed mantle cell lymphoma as an appendiceal volvulus, highlighting an unusual cause of acute abdominal pain requiring emergent surgery.

This case report describes the rare but life-threatening development of disseminated intravascular coagulation (DIC) in a patient with the typically indolent, asymptomatic leukemic non-nodal variant of MCL.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This study identifies a rare CD5/SOX11 double-negative pleomorphic MCL, showing CCND1 rearrangement is the key feature to differentiate it from cyclin D1-positive DLBCL, ensuring correct diagnosis.